Supernus Pharmaceuticals financials at a glance
| Year | Year | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2011 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$1.48M | $12.02M | $92.68M | $147.47M | $215.00M | $302.24M | $408.90M | $392.76M | $520.40M | $0.80M | $579.78M | $667.24M | $607.52M | $0.00M |
| GM % | Gross Margin % |
|
100.00% | 90.81% | 93.79% | 94.29% | 94.43% | 94.97% | 96.24% | 95.76% | 89.92% | 100.00% | 87.05% | 86.93% | 86.21% | 0.00% |
| OM | Operating Margin |
|
0.00% | 0.00% | -5.69% | 14.13% | 25.22% | 32.93% | 35.33% | 37.83% | 35.36% | 0.00% | 13.71% | 6.84% | 2.21% | 0.00% |
| EPS | Earnings Per Share |
|
$-16.60 | $-2.72 | $-2.18 | $-0.24 | $0.32 | $1.78 | $1.08 | $2.05 | $2.10 | $2.36 | $0.98 | $2.65 | $1.14 | $0.00 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| PR % | Payout Ratio % |
|
-0.00% | -0.00% | -0.00% | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sha. | Shares |
|
30.47m | 33.84m | 42.93m | 48.92m | 49.51m | 51.26m | 52.26m | 52.46m | 52.69m | 0m | 53.18m | 53.39m | 0m | 54.63m |
| OCF | Operating Cash Flow |
|
$-47.20M | $-57.95M | $-24.50M | $34.52M | $66.81M | $114.64M | $128.99M | $143.13M | $138.40M | $-36.19M | $127.13M | $116.83M | $111.09M | $0.00M |
| FCF | Free Cash Flow |
|
$-47.95M | $-59.60M | $14.70M | $30.02M | $65.21M | $112.61M | $128.14M | $140.39M | $134.95M | $-36.88M | $125.08M | $116.41M | $118.70M | $0.00M |
| FCFS | Free Cash Flow Per Share |
|
$-2.75 | $-1.87 | $-0.59 | $0.68 | $1.32 | $2.22 | $2.46 | $2.70 | $2.56 | $-22.97 | $2.36 | $2.17 | $2.03 | $0.00 |